Healthcare utilization and cost of pneumococcal disease in the United States (Q44371658)

2 December 2017

title

Healthcare utilization and cost of pneumococcal disease in the United States (English)

1 reference

2 December 2017

author

Jonathan A Finkelstein

11

object named as

Jonathan A Finkelstein

1 reference

2 December 2017

5

Tracy A Lieu

1 reference

2 December 2017

1

Susan S Huang

1 reference

2 December 2017

7

Elizabeth R Zell

1 reference

2 December 2017

9

Carlos G Grijalva

1 reference

2 December 2017

Kristen M Johnson

2

1 reference

2 December 2017

G Thomas Ray

3

1 reference

2 December 2017

Peter Wroe

4

1 reference

2 December 2017

Matthew R Moore

6

1 reference

2 December 2017

Jeffrey A Linder

8

1 reference

2 December 2017

Joshua P Metlay

10

1 reference

2 December 2017

language of work or name

English

0 references

publication date

11 March 2011

1 reference

2 December 2017

1 reference

2 December 2017

volume

29

1 reference

2 December 2017

issue

18

1 reference

2 December 2017

page(s)

3398-3412

1 reference

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005

7 January 2021

2 references

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

7 January 2021

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

inferred from DOI database lookup

7 January 2021

based on heuristic

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Continued impact of pneumococcal conjugate vaccine on carriage in young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Criteria-based diagnosis and antibiotic overuse for upper respiratory infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Bacteriological findings in nasopharynx specimens from patients with a clinical diagnosis of acute sinusitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Diagnosis and management of acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Economic productivity by age and sex: 2007 estimates for the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Costs of otitis media in a managed care population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Adults with invasive pneumococcal disease: missed opportunities for vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Immunological responses to pneumococcal vaccine in frail older people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

Pneumococcal Conjugate Vaccine, Polysaccharide Vaccine, or Both for Adults? We’re Not There Yet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.02.088

10.1016/J.VACCINE.2011.02.088

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference